NCT06382493 Tegoprazan-containing Sequential for H. Pylori
| NCT ID | NCT06382493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Bundang Hospital |
| Condition | Helicobacter Pylori Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2026-12-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2021-02-01 with a primary completion date of 2026-12-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy
Eligibility Criteria
Inclusion Criteria: Patients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining) Exclusion Criteria: * congestive heart failure, NYHA III or IV * end-stage renal disease * alcoholics * drug abusers * pregnant or nursing women
Contact & Investigator
Nayoung Kim, Prof.
PRINCIPAL INVESTIGATOR
Seoul National University Bundang Hospital
Frequently Asked Questions
Who can join the NCT06382493 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Helicobacter Pylori Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06382493 currently recruiting?
Yes, NCT06382493 is actively recruiting participants. Contact the research team at saludos@naver.com for enrollment information.
Where is the NCT06382493 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT06382493 clinical trial?
NCT06382493 is sponsored by Seoul National University Bundang Hospital. The principal investigator is Nayoung Kim, Prof. at Seoul National University Bundang Hospital. The trial plans to enroll 400 participants.